Monoclonal antibodyPhase 3 trialInvestigational

Tafasitamab

How it works

Binds to the CD19 protein on CLL cells, marking them for destruction by the immune system.

Cancer types

Leukemia— CD19-positive

Efficacy

In clinical trials, around 80% of patients achieved a complete or partial response, with a median progression-free survival of approximately 6 months.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

Evidence from research

Study	Cancer type	Stage	Efficacy
New Study Explores Tafasitamab in Relapsed/Refractory B-Cell Leukemia	Leukemia	phase-2	The overall response rate was 9%.	Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.